Industry and Technology Minister Mustafa Varank, Covidien TUBITAK-19 VLP-based vaccine human trial of the work under the umbrella of Turkey to join the Platform Phase 1 phase was under observation at Ankara Oncology Hospital.
Minister Varank and TÜBİTAK President Prof. Dr. Hasan Mandal came to Ankara Oncology Hospital Phase 19 Clinical Research Center in the morning. Ankara Oncology Training and Research Hospital Chief Physician Prof. Dr. Fevzi Altuntaş and Clinical Research Center Coordinator Assoc. Dr. Halil Kara was accompanied. It was learned that the first dose of vaccine will be administered to Minister Varank, whose blood tests and clinical parameters including ECG are monitored. Varank, who will spend the night in the hospital, is expected to be discharged tomorrow.
Unlike vaccines VLP vaccine which was introduced in Turkey, not to be under the skin into the muscle from the arm by subcutaneous injection method. Minister Varank will receive the second dose of vaccine after 21 days.
36 PEOPLE PARTICIPATE IN HUMAN TRIALS
Prof. Dr. Human trials of the VLP vaccine candidate, developed as a result of the joint project of Mayda Gürsel and Bilkent University İhsan Gürsel couple, are applied to two groups of 18 plus 18, one low and one high dose. Six of both groups were placebo. In other words, it consists of injections that do not contain an active or active substance.
PHASE 2 IS SUITABLE FOR BRITISH VARIANT
The names of the volunteers, except for Minister Varank and TÜBİTAK President Mandal, are kept confidential. The healthcare personnel administering the vaccine cannot have information about the content of the injection in the person being administered. The innovative vaccine candidate of the Gürsel couple is expected to move to Phase 2 in June and Phase 3 in August. Phase 2 study of the native VLP vaccine candidate prepared according to the British variant.
ANNOUNCEMENT IN THE WORLD, ONE IN TURKEY
World No. TÜBİTAK Covidien-19 Turkey Platform covered by the vaccine candidate developed with a single VLP technology, taking place in the WHO Covidien-30 vaccine candidates list March 19 clinical stage this kind in the world was the 4th vaccine candidate.
PRODUCTION BASE GEBZE
Varank, Mayda and İhsan Gürsel visited Nobel İlaç's Biotechnological Medicine Facility in Gebze TÜBİTAK Marmara Teknokent (MARTEK) in January to see the work of their teachers on site.
IMITING THE VIRUS
In VLP type vaccines, the developed virus-like particles mimic the virus in a way that does not cause infection. While these particles induce an immune response, they do not cause illness.
VACCINE ANTIGEN WITH 4 PROTEINS
Another feature of the vaccine candidate developed by the Gürsel couple is that, unlike other VLP vaccines, this platform uses 4 structural proteins of the virus as vaccine antigens. In this respect, there is no vaccine candidate entering the phase of clinical human trials in the world.